Nature Reviews Rheumatology最新文献_第6页

Joint-specific susceptibility to inflammation is determined in utero 关节对炎症的敏感性是在子宫内确定的。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2026-07-02 DOI: 10.1038/s41584-026-01403-4

Holly Webster

引用次数: 0

Time to rethink the treatment of palindromic rheumatism 是时候重新思考风湿病的治疗了。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2026-07-01 DOI: 10.1038/s41584-026-01400-7

Kulveer Mankia

引用次数: 0

Sensory nerves protect against tendon degeneration 感觉神经防止肌腱退化。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2026-06-29 DOI: 10.1038/s41584-026-01398-y

Holly Webster

引用次数: 0

Publisher Correction: TLR7 in systemic lupus erythematosus: genetics and emerging therapies TLR7在系统性红斑狼疮中的作用：遗传学和新兴疗法。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2026-06-26 DOI: 10.1038/s41584-026-01401-6

Carola G. Vinuesa, Madhumita Shrotri, Anisur Rahman

引用次数: 0

TLR7 in systemic lupus erythematosus: genetics and emerging therapies TLR7在系统性红斑狼疮中的作用：遗传学和新兴疗法。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2026-06-19 DOI: 10.1038/s41584-026-01388-0

Carola G. Vinuesa, Madhumita Shrotri, Anisur Rahman

{"title":"TLR7 in systemic lupus erythematosus: genetics and emerging therapies","authors":"Carola G. Vinuesa, Madhumita Shrotri, Anisur Rahman","doi":"10.1038/s41584-026-01388-0","DOIUrl":"10.1038/s41584-026-01388-0","url":null,"abstract":"Systemic lupus erythematosus (SLE) is a disease with considerable unmet treatment needs. Endosomal nucleic acid sensing by Toll-like receptor 7 (TLR7) is emerging as a key pathogenic pathway. Gain-of-function mutations in the genes encoding TLR7 and its chaperone UNC93B1 can cause monogenic childhood-onset SLE; rare variants in proteins that regulate ligand availability or downstream signalling proteins also contribute to disease. TLR7 variants can increase the affinity of this receptor for its ligands and can alter binding to endogenous antagonists. Both self RNA–protein complexes and viruses have been implicated in TLR7 activation. Key pathogenic mechanisms include breakdown in B cell tolerance and autoantibody production and type I interferon secretion. Although current therapies such as B cell-depleting chimeric antigen receptor (CAR) T cells and anifrolumab (anti-type I interferon receptor) offer benefit, they are limited by high costs and lack of oral options. In this context, TLR7 has emerged as a promising therapeutic target. Phase II trials of an oral dual TLR7–TLR8 antagonist show durable suppression of the interferon signature in all patients, indicating that TLR7 and TLR8 drive this signature in SLE. This treatment has shown clinical benefit for SLE and cutaneous lupus erythematosus, although the primary endpoint (a dose–response effect) was only met in cutaneous lupus erythematosus. Thus, TLR7–TLR8 antagonists might reshape SLE treatment, alone or in combination with other drugs. Targeting Toll-like receptor 7 (TLR7) represents a promising therapeutic strategy for the treatment of systemic lupus erythematosus (SLE). This Review provides mechanistic insights into the roles of TLR7 and its associated agonistic and antagonistic ligands in SLE and highlights emerging clinical data on therapeutics that target TLR7 for the treatment of SLE.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"22 8","pages":"479-495"},"PeriodicalIF":33.7,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148283826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lung disease in rheumatoid arthritis 类风湿关节炎中的肺部疾病。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2026-06-18 DOI: 10.1038/s41584-026-01394-2

Elisabeth Bendstrup, Philippe Dieude, Michael Kreuter, Anna-Maria Hoffmann-Vold, Vincent Cottin, Ellen M. Hauge

{"title":"Lung disease in rheumatoid arthritis","authors":"Elisabeth Bendstrup, Philippe Dieude, Michael Kreuter, Anna-Maria Hoffmann-Vold, Vincent Cottin, Ellen M. Hauge","doi":"10.1038/s41584-026-01394-2","DOIUrl":"10.1038/s41584-026-01394-2","url":null,"abstract":"Rheumatoid arthritis (RA) is a prevalent chronic systemic autoimmune inflammatory disease that primarily targets synovial joints and periarticular tissues. In RA, systemic inflammation has been associated with extra-articular manifestations, including pulmonary involvement, which are leading causes of reduced survival. Tobacco smoking is a well-established risk factor for anti-citrullinated protein antibody (ACPA)-positive RA and is also associated with chronic obstructive pulmonary disease, interstitial lung disease (ILD) and lung cancer, the prevalence of which is elevated in people with RA. Pulmonary manifestations such as airway obstructive disease, ILD and bronchiolitis affect a substantial proportion of people with RA. Screening for pulmonary disease, particularly ILD, is gaining emphasis, with high-resolution CT recommended based on risk factors including age, sex, antibody status and smoking. Despite advances in therapies to effectively manage joint inflammation, evidence-based treatments for RA-associated ILD remain limited. Chronic obstructive pulmonary disease and bronchiectasis in RA warrant more recognition owing to their effect on morbidity and mortality, and should be managed in accordance with current international treatment guidelines for these conditions. This Review summarizes the pathophysiology of lung involvement in RA, diagnostic challenges and evolving management strategies aimed at optimizing patient outcomes. This Review examines the latest findings related to the pathophysiology of lung involvement in rheumatoid arthritis (RA), describes the most common forms of RA-associated pulmonary disease and reviews current evidence on the screening, diagnosis, treatment and prognosis of RA-related lung disease.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"22 9","pages":"558-570"},"PeriodicalIF":33.7,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148278126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis 类风湿关节炎的诊断、预后和治疗生物标志物。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2026-06-15 DOI: 10.1038/s41584-026-01391-5

Zoltán Szekanecz, Lilla Gunkl-Tóth, Szilvia Szamosi, Diane van der Woude, Iain McInnes, György Nagy

{"title":"Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis","authors":"Zoltán Szekanecz, Lilla Gunkl-Tóth, Szilvia Szamosi, Diane van der Woude, Iain McInnes, György Nagy","doi":"10.1038/s41584-026-01391-5","DOIUrl":"10.1038/s41584-026-01391-5","url":null,"abstract":"Outcomes in rheumatoid arthritis (RA) have improved considerably with the advent of new therapeutic modalities, improved therapeutic strategies and greater recognition of the need to manage comorbidities. Nevertheless, unmet needs remain. Sustained remission is achieved by only a minority of patients, in part owing to delays in diagnosis, imprecise risk stratification and suboptimal treatment selection. A pressing need therefore exists for robust diagnostic and prognostic tools to support clinical decision making. Advances in genetic, protein, imaging and multi-omics biomarkers offer opportunities to refine RA diagnosis, predict disease course and guide therapeutic choices. Parallel progress in biomarker discovery is also shaping understanding of major RA-associated comorbidities, including cardiovascular disease, interstitial lung disease, osteoporosis and malignancy. Together, clinical introduction of such biomarkers could enable earlier intervention, more precise therapy and improved outcomes for patients with RA. This Review examines emerging laboratory, imaging and multi-omics biomarkers in rheumatoid arthritis, highlighting roles in diagnosis, prognosis, treatment selection and comorbidity management, and emphasizing challenges and opportunities for translating biomarker advances into routine clinical practice and improved patient outcomes.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"22 8","pages":"496-513"},"PeriodicalIF":33.7,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148258939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

20 years of progress in the classification of immune-mediated diseases 免疫介导疾病分类的20年进展。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2026-06-08 DOI: 10.1038/s41584-026-01390-6

Dennis McGonagle, Daniel L. Kastner, Ivona Aksentijevich

引用次数: 0

Anti-CD19 CAR T cell therapy promotes skin remodelling in systemic sclerosis 抗cd19 CAR - T细胞疗法促进系统性硬化症的皮肤重塑。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2026-06-08 DOI: 10.1038/s41584-026-01396-0

Holly Webster

引用次数: 0

Progress made and the road ahead for cancer screening in myositis 肌炎癌症筛查的进展与未来之路。